The EASL SLD Summit 2025 offers a comprehensive exploration of steatotic liver disease, over three days. The programme integrates practical clinical education with the latest research updates.

The first day opens with a session titled “The trajectory of people living with Steatotic Liver Disease: a clinical update and consensus.” This session will feature talks covering aspects from prevention to end-stage disease management, including key stakeholders. Participants will help create a consensus document for holistic management, including pediatric care.

Also on the first day, the summit will host the “Endpoint Conference on ALD and MetALD in Phase 2 and 3 clinical trials“. This conference focuses on improving clinical trial design, execution, and evaluation for ALD and MetALD, aiming to enhance patient outcomes. It will address the progression from fibrosis to decompensated cirrhosis, the use of invasive versus non-invasive tests as endpoints, and the role of MASH methodologies in informing clinical trials for ALD and MetALD.

On 24 and 25 January, the summit’s core programme will delve into the latest innovations and insights in MASLD, MetALD, and ALD. Attendees will gain a holistic understanding of SLD, from research findings to the practical implications for patient care. This summit fosters networking among scientists, healthcare providers and public health experts with common interests in SLD.

Add event to calendar